Biotechnology firms that are happy to remain private while US stock market investors continue to thrash public drug developers are benefitting from the industry's ongoing venture capital boom, including Annexon Bioscience Inc., Mersana Therapeutics Inc. and six other US and EU companies.
The Nasdaq Biotechnology Index (NBI) has fallen 33.2% during the past year and only one therapeutics company has gone public...





![Spotlight On RDCs, AOCs As Leading Novel Bioconjugates[Updated]](https://web.insights.norstella-labs.com/resizer/v2/3M7ZAWZOBNK7NG4A4WDOIFG6DU.jpg?smart=true&auth=392a1fdb3cfacb29445720c412410e598dbcc5f90f14857652cd498bd0faa0fb&width=400&height=225)
